Xylitol
Phase 1Small molecule
Xylitol is one of 56 small molecule programs targeting Inflammatory Bowel Disease. It is currently in Phase 1.
2
Indications
11
Total Trials
2
Active Trials
55
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
62 competitors in Inflammatory Bowel Disease
#DrugCompanyPhaseTrials
1Remicade
Johnson & JohnsonApproved
Skyrizi
AbbVieApproved
Dificlir
Merck & Co.Approved
Humira
RRanbaxy Laboratories Limited
Approved
Zyloprim
Jazz PharmaceuticalsApproved
Elavil
AstraZenecaApproved
Mounjaro
Eli LillyApproved
Calciferol
Jazz PharmaceuticalsApproved
Avandia
Jazz PharmaceuticalsApproved
Vancocin
HHikma Pharmaceuticals LLC
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Cystic Fibrosis2 trials
Chlorhexidine1 trial
Anticaries Effect of Xylitol,Probiotic and Chlorhexidine Mouth Rinses Among Individuals at High Risk
Completed·—·Phase 2/3·NCT04399161·60 enrolled
Acute otitis media1 trial
Xylitol Syrup for the Prevention of Acute Otitis Media in Otitis-prone Children
Completed·—·Phase 3·NCT01044030·326 enrolled
4 more indications
Stem Cell Transplant Patients1 trial
Xylitol - Healthcare Associated Infection Reduction in Stem Cell Transplant Patients
Terminated·—·Phase 2·NCT04117477·46 enrolled
Inflammatory Bowel Disease1 trial
Pilot Trial of Xylitol for C. Difficile De-Colonization in Patients With Inflammatory Bowel Disease
Not yet recruiting·—·Phase 1·NCT06799039·69 enrolled
Colonization1 trial
Xylitol Use for Decolonization of C. Difficile in Patients With IBD
Not yet recruiting·—·Phase 1·NCT05852587·99 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Xylitol. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- JJoseph Zabner